Collaboration and License Agreements - Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Contract Assets
Accounts receivable, net	$ 19,320		$ 25,155
Unbilled accounts receivable	2,595		11,875
Contract Liabilities
Contract liabilities, current	4,629		11,510
Contract liabilities, noncurrent	11,995		25,066
Accrued expenses, current	62,119		68,164
Collaborative Arrangement | Roche, Collaboration (Pralsetnib) Agreement
Contract Assets
Accounts receivable, net			2,679
Unbilled accounts receivable			6,802
Contract Liabilities
Accrued expenses	577
Collaborative Arrangement | Roche, Collaboration and License (Immunotherapy) Agreement
Contract Liabilities
Contract liabilities	16,589		31,405
Contract liabilities, current	4,594		6,339
Contract liabilities, noncurrent	11,995		25,066
Accrued expenses	13,938
Accrued expenses, current	8,208
Accrued expenses, noncurrent	5,730
Collaborative Arrangement | Roche, Collaboration and License (Immunotherapy) Agreement, Phase I Clinical Trials
Contract Liabilities
Accrued expenses		$ 15,000
Collaborative Arrangement | Clementia
Contract Liabilities
Contract liabilities	0		0
Collaborative Arrangement | C Stone
Contract Assets
Accounts receivable, net	2,045		8,164
Unbilled accounts receivable	2,206		5,034
Contract Liabilities
Contract liabilities	$ 0		$ 4,800